Francis Pang is Vice President and Head, Global Market Access at Orchard Therapeutics and has more than 20 years of experience in pricing and reimbursement, market access and health economics. Most recently, Francis was global head of market access at Amicus Therapeutics, where he helped achieve broad reimbursement for an oral treatment for Fabry Disease in more than 20 markets worldwide. Prior to his role at Amicus, Francis served as vice president of market access for Biogen where he established and built the company’s market access capability across Europe and Canada. His rare diseases experience began in 2009 when he joined Shire Human Genetic Therapies as senior director of market access and public affairs focused in the Europe, the Middle East and Africa (EMEA) region, responsible for the pricing and reimbursement of the lysosomal storage disease and hereditary angioedema orphan drug portfolio. In recognition of his expertise in health economics related to rare diseases, Francis has served as the healthcare industry representative on the NICE Highly Specialised Technologies (HST) Committee since its inception.
Prior to his work in the biopharmaceutical industry, Francis was the inaugural Pharmacoeconomics Research Fellow at the Centre for Health Economics, University of York and Monbusho Scholar at Kyoto University, Japan. Francis holds degrees in genetics and health economics, together with an MBA from INSEAD and certification in the management of biotech ventures from École Polytechnique Fédérale de Lausanne (EPFL), a research institute and university in Lausanne, Switzerland.